The Europe Bovine Respiratory Disease Treatment Market has been estimated at USD 9.18 million in 2018 and is projected to reach USD 23.34 million by 2023, at a CAGR of 20.5% during the forecast period from 2018 to 2023. There is a huge influence of bovine respiratory disease (BRD), diarrhoea, arthritis and otitis on the economically significant parameters of mortality, hot carcass weight (HCW), carcass quality, fat cover and meat colour which produces problem for the cattle production.
BRD is a complex multi-factorial disease that involves an interaction between several factors. In the current scenario body temperature has been used to determine whether treatment should be done or not. Body temperature is such an important diagnostic test that many feedlots will treat animals based upon an undifferentiated fever.
A combination of disease organisms is usually accountable for the respiratory infection and illness, but other factors also affect the animal’s health. Environmental factors, particularly transport, have been associated with BRD; weather has always been implicated in the occurrence of the disease. It has been concluded that stressful events, and others like calving or an overenthusiastic introduction to high grain rations, may precipitate cases of BRD.
The Europe bovine respiratory disease treatment market has been segmented on the basis of type of treatment into anti-infectious agents, anti-parasiticides, bronchodilators, oral rehydration fluids, non-steroidal anti-inflammatories, and mucolytic. Anti-infectious can be further sub-segmented into antibiotics and sulfas. Antibiotics and anti-inflammatory drugs are now being used for combination treatment and expected to improve the success rate of the treatment. Geographically Europe market is segmented into France, Italy, Spain, Germany and UK.
The major companies dominating this market by their products and services are Zoetis Inc., Merck & Co. Inc., Bayer Corporation, Eli Lilly & Co., Merial S.A.S, Boehringer Ingelheim Vetmedica, Novartis Animal Health, Vibrac S.A, Ceva Sante Animale and Vétoquinol S.A.
1. Introduction
1.1 Market Definition
1.2 Study Deliverables
1.3 Base Currency, Base Year and Forecast Periods
1.4 General Study Assumptions
2. Research Methodology
2.1 Introduction
2.2 Research Phases
2.2.1 Secondary Research
2.2.2 Primary Research
2.2.3 Econometric Modelling
2.2.4 Expert Validation
2.3 Analysis Design
2.4 Study Timeline
3. Overview
3.1 Executive Summary
3.2 Key Inferences
3.3 New Developments
4. Drivers, Restraints, Opportunities, and Challenges Analysis (DROC)
4.1 Market Drivers
4.2 Market Restraints
4.3 Key Challenges
4.4 Current Opportunities in the Market
5. Market Segmentation
5.1 By Type of Treatment
5.1.1 Anti-Infectious Agents
5.1.1.1 Antibiotics
5.1.1.2 Sulfas
5.1.2 Anti-Parasiticides
5.1.3 Bronchodilators
5.1.4 Oral Rehydration Fluids
5.1.5 Non-Steroidal Anti-Inflammatories
5.1.6 Mucolytics
6. Geographical Analysis
6.1 Introduction
6.2 U.K
6.3 Spain
6.4 Germany
6.5 Italy
6.6 France
7. Strategic Analysis
7.1 PESTLE analysis
7.1.1 Political
7.1.2 Economic
7.1.3 Social
7.1.4 Technological
7.1.5 Legal
7.1.6 Environmental
7.2 Porter’s Five analysis
7.2.1 Bargaining Power of Suppliers
7.2.2 Bargaining Power of Consumers
7.2.3 Threat of New Entrants
7.2.4 Threat of Substitute Products and Services
7.2.5 Competitive Rivalry within the Industry
8. Market Leaders' Analysis
8.1 Zoetis Inc.
8.1.1 Overview
8.1.2 Product Analysis
8.1.3 Strategic Evaluation and Operations
8.1.4 Financial analysis
8.1.5 Legal issues
8.1.6 Recent Developments
8.1.7 SWOT analysis
8.1.8 Analyst View
8.2 Merck & Co. Inc.
8.3 Bayer Corporation
8.4 Eli Lilly & Co.
8.5 Merial S.A.S
8.6 Boehringer Ingelheim Vetmedica
8.7 Novartis Animal Health
8.8 Vibrac S.A
8.9 Ceva Sante Animale
8.10 Vétoquinol S.A.
9. Competitive Landscape
9.1 Market share analysis
9.2 Merger and Acquisition Analysis
9.3 Agreements, collaborations and Joint Ventures
9.4 New Product Launches
10. Expert Opinions
10.1 Market Outlook
10.2 Investment Opportunities
Appendix
a) List of Tables
b) List of Figures
